Coherus Oncology (CHRS) Total Current Liabilities (2013 - 2026)

Coherus Oncology has disclosed Total Current Liabilities across 14 years of filings, most recently posting $75.5 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 71.36% year-over-year to $75.5 million; the TTM figure through Jun 2026 stood at $75.5 million (down 71.36% YoY), while the FY2025 annual figure was $140.4 million, down 50.39% from the prior year.
• Total Current Liabilities came in at $75.5 million for Q2 2026 at Coherus Oncology, down from $132.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $538.3 million in Q1 2024 to a low of $75.5 million in Q2 2026.
• Average Total Current Liabilities over 5 years is $238.2 million, with a median of $205.5 million recorded in 2022.
• Year-over-year, Total Current Liabilities soared 336.2% in 2024 and plunged 71.36% in 2026.
• Over 5 years, Total Current Liabilities stood at $138.7 million in 2022, then jumped by 139.21% to $331.8 million in 2023, then dropped by 14.71% to $283.0 million in 2024, then slumped by 50.39% to $140.4 million in 2025, then plunged by 46.21% to $75.5 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $75.5 million in Q2 2026, $132.3 million in Q1 2026, and $140.4 million in Q4 2025.